Findings highlight the need for positive messaging targeting potential PrEP users and their social networks to increase PrEP acceptance and uptake.

Section 1 Diagnoses of HIV Infection and Diagnoses of Infection Classified as Stage 3 (AIDS) 1a Diagnoses of HIV infection, by year of diagnosis and selected characteristics, 2012-2017-United States 1b Diagnoses of HIV infection, by year of diagnosis and selected characteristics, 2012-2017-United States and 6 dependent areas 2a Stage 3 (AIDS), by year of diagnosis and selected characteristics, 2012-2017 and cumulative-United States 2b Stage 3 (AIDS), by year of diagnosis and selected characteristics, 2012-2017 and cumulative-United States and 6 dependent areas 3a Diagnoses of HIV infection, by race/ethnicity and selected characteristics, 2017-United States 3b Diagnoses of HIV infection, by race/ethnicity and selected characteristics, 2017-United States and 6 dependent areas 4a Stage 3 (AIDS), by race/ethnicity and selected characteristics, 2017-United States 4b Stage 3 (AIDS), by race/ethnicity and selected characteristics, 2017-United States and 6 dependent areas 5a Diagnoses of HIV infection among adults and adolescents, by year of diagnosis, sex, and selected characteristics, 2012-2017-United States 5b Diagnoses of HIV infection among adults and adolescents, by year of diagnosis, sex, and selected characteristics, 2012-2017-United States and 6 dependent areas 6a Stage 3 (AIDS) among adults and adolescents, by year of diagnosis, sex, and selected characteristics, 2012-2017-United States 6b Stage 3 (AIDS) among adults and adolescents, by year of diagnosis, sex, and selected characteristics, 2012-2017-United States and 6 dependent areas 7a Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected characteristics, 2012-2017-United States 7b Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected characteristics, 2012-2017-United States and 6 dependent areas 8a Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2012-2017-United States 8b Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2012-2017-United States and 6 dependent areas 9a Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2012-2017-United States 9b Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2012-2017-United States and 6 dependent areas 10a Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected characteristics, 2012-2017-United States 10b Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected characteristics, 2012-2017-United States and 6 dependent areas  HIV Surveillance Report 4 Vol. 29 15 Stage 3 (AIDS) among children aged <13 years, by year of diagnosis, 1992-2017-United States and 6 dependent areas 16 Diagnoses of HIV infection among adult and adolescent Hispanics/Latinos, by transmissio...

No abstract

No abstract

No abstract

No abstract

We evaluated the acceptability and impact of a web-based PrEP educational video among women ( n = 126) by comparing two Planned Parenthood centers: one assigned to a Web Video Condition and one to a Standard Condition. Most women reported the video helped them better understand what PrEP is (92%), how PrEP works (93%), and how to take PrEP (92%). One month post-intervention, more women in the Web Video Condition reported a high level of comfort discussing PrEP with a provider (82% vs. 48%) and commonly thinking about PrEP (36% vs. 4%). No women with linked medical records initiated PrEP during 1-year follow-up. Supplementary Information The online version contains supplementary material available at 10.1007/s10461-021-03210-2.

Integrating pregnancy and HIV prevention services would make reproductive health care settings an optimal venue for the promotion and delivery of preexposure prophylaxis (PrEP) to cisgender women. However, these settings have been slow to adopt PrEP. Planned parenthood clinicians and leaders possess critical insight that can help accelerate PrEP implementation in reproductive health care settings and elements of the Consolidated Framework for Implementation Research (i.e., relative priority of the intervention to staff, implementation climate, available resources to implement the intervention, and staff access to knowledge and information about the intervention) can shed light on elements of Planned Parenthood’s inner setting that can facilitate PrEP implementation. In this study, individual 60-min interviews were conducted with clinical care team members (n = 10), leadership team members (n = 6), and center managers (n = 2) to explore their perspectives on PrEP implementation and associated training needs. Transcripts were transcribed verbatim and thematically analyzed. Despite having variable PrEP knowledge, participants (100% women, 61% non-Hispanic White) expressed positive attitudes toward implementing PrEP. Barriers and facilitators toward providing PrEP were reported at the structural, provider, and patient levels. Participants desired PrEP training that incorporated culturally competent patient-provider communication. Although participants identified ways that Planned Parenthood uniquely enabled PrEP implementation, barriers must be overcome to optimize promotion and delivery of PrEP to cisgender women.